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Background: Systemic lupus erythematosus is associated with an increased risk of developing 
an endocrine disease. These endocrinopathies can closely mimic SLE symptons ranging from 
fatigue to renal involvement but the treatment is often very different.   Methods: A careful 
review of the PubMed and MEsH databases linking endocrine disease to SLE was performed. A 
retrospective analysis of the 708 SLE patient cohort at University College London Hospital 
(UCLH) has been completed. They have been followed for at least one year from 1978 to 2017. 
In our study, we reported how often these endocrine diseases are identified in lupus patients 
compared to the general population and whether these patients with both diseases had a 
poorer prognosis. We have attempted to establish if the endocrine diseases develop before or 
after the lupus diagnosis.    Results: The literature search produced some conflicting results. 
708 SLE patients were included in our study. We found 67 endocrine disease in 55 different 
patients of our cohort. The most common endocrinopathy was hypothyroidism (5.22%) 
followed by type 2 diabetes mellitus (1.41%) and hyperthyroidism (1.41%). Other endocrine 
disorders also identified were type 1 diabetes mellitus (0.42%) and hyperparathyroidism 
(0.70%). In terms of mortality, lupus patients with concomitant endocrine disease had similar 
outcomes compared to those without endocrine disease (16.36% died versus 15.16%). In 
general terms, these endocrine diseases were developed after the lupus diagnosis. We found 
that the 21.8 % of our SLE plus endocrinopathy patients also have an increased risk of 
developing a second endocrine disease. Conclusion: We report concomitant endocrine disease 
in 7.76 % of our 708 SLE cohort followed, for almost 40 years, at UCLH. These patients have 
increased liability to develop a second endocrine disease, but overall there is no difference in 
terms of mortality between SLE patients with or without an endocrinopathy. It is important to 
capture endocrine diseases in SLE as the symptoms they cause may mimic SLE features,but 
require quite distinct treatment. 
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INTRODUCTION: 
 
Systemic lupus erythematosus (SLE) is an autoimmune rheumatic disorder 
characterized by many clinical manifestations often involving several organs and 
systems. Thus patients have a variable prognosis and often experience a reduced 
quality of life. 
Patients with SLE may also develop a range of endocrine diseases, such as; 
hypothyroidism, hyperthyroidism or Addison’s disease[8,29-30]. Given that endocrine 
diseases may cause symptoms ranging from fatigue to severe renal impairment that 
can mimic features of SLE, it is clearly important to diagnose them quickly and treat 
them appropriately. 
Different international studies have studied the prevalence of endocrine diseases in 
SLE patients compared with the normal population and they vary considerably. In this 
review, we have analysed the literature linking endocrine diseases with SLE. We have 
focused on: hypothyroidism, hyperthyroidism, type I diabetes mellitus (T1DM) and 
type II diabetes mellitus (T2DM), hyperparathyroidism, hypoparathyroidism and 
Addison’s disease. 
We reviewed the prevalence of these endocrinopathies in SLE patients noting ranges 
of: hyperthyroidism: 0-5.19 %, [1-4,6,11-15,32]; hypothyroidism: 2.7-21.5 %, [1-6,11-19,32] and  
diabetes mellitus (DM): 1.85-3.3 %, [7,10,11,31]. Most studies have observed an increased 
prevalence of hypothyroidism, [1-6,11-19,32] in SLE patients, compared to the normal 
population. With regard to hyperthyroidism, [1-4,6,11-15,32]; and T1DM/T2DM, [7,10,11,31], 
different results have been reported. A few case reports of Addison’s disease in SLE 
patients have been published and no prevalence study is available to date. 
In addition, we have carefully reviewed the occurrence of endocrine diseases 
identified among the 708 patients followed up at University College Hospital (UCLH) 
from 1978 to 2017. We have also considered the temporal relationship between the 
onset of SLE and the various endocrine diseases. We wondered whether those patients 
with endocrine diseases were more likely to have a second endocrine disease. Finally, 
we sought to determine whether those patients with concomitant endocrine disease 
have a poorer prognosis. 
 
METHODS:  
We have carefully reviewed the world literature linking lupus and endocrine diseases 
in the main databases (PUBMED, MEsH). The terms used for the search were: “lupus 
and hypothyroidism”, “lupus and hyperthyroidism”, “lupus and diabetes mellitus”, 
“lupus and hyperparathyroidism”, “lupus and hypoparathyroidism”, “lupus and 
Addison's disease”. 
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We reviewed around 80 publications including studies, reviews and case reports in two 
languages (Spanish [10,24,28] and English). These studies ranged from October 1987 to 
November 2017. 
A retrospective analysis has been completed using the UCLH SLE patient database for 
this report. We have extracted data from our 708 SLE patients, all whom have fulfilled 
the revised American College of Rheumatology (ACR) SLE classification criteria,9. They 
have been regularly reviewed at the UCLH from 1978 to 2017 and have completed a 
minimum of one year follow-up. Data on the development of endocrine disease in our 
lupus cohort has been collected prospectively from 1978. To make sure we were not 
missing any endocrine diseases we undertook a very detailed review of a random 
selection of cases (not known to have endocrine problems) to ensure we were not 
missing any key data. Among our SLE cohort, the 91.6% (649) were women and the 
8.3% (59) were men. 
We have attempted to establish if endocrine diseases develop before or after the SLE 
diagnosis. We have also reviewed the hospital notes from rheumatology and 
endocrinology during the follow-up period. 
In addition, we have checked the different blood test parameters which are 
characteristic of these diseases (TSH, T4, glycemia, glycated haemoglobin, anti-thyroid 
antibodies [ microsomal, thyroglobulin and thyroid hormone anti-receptor 
autoantibodies] cortisol, vitamin D and ACTH).  
 
 
RESULTS: 
Patient characteristics 
All 708 SLE patients in the UCLH cohort were included in this study.  
We identified 67 endocrine diseases (see table 1) in 55 different patients (7.76% of the 
total lupus cohort). Our detailed review of 100 patients not recorded as having 
endocrine diseases reassured us as no ‘unexpected’ conditions were identified. The 
diagnoses were invariably confirmed by an endocrinologist. Furthermore, 21.8 % of 
those with one endocrine disorder had more than one of these conditions. 
Representative prevalence studies showing the extreme among the cohort reported 
are shown in table 2. 
 
SLE&Hypothyroidism 
We found a total of 37 SLE patients with clinical hypothyroidism (5.22 % of the total in 
the UCLH SLE cohort). Among these patients, 16 had one or more of the thyroid 
antibodies tested positive. 11 of them had negative thyroid antibodies and in 10 cases 
we could not identify the results. 
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We determined whether hypothyroidism was more likely to appear after or before the 
SLE diagnosis. In 17 patients, the hypothyroidism appeared later [ range: 3-35 years; 
mean: 12 years; median: 9 years]. In 11 patients, the hypothyroidism appeared before 
[range: 1-12 years, mean: 5.45 years; median: 4 years]. In 9 cases we had insufficient 
data to be certain. 
In addition, we have observed that 12 of these 37 patients with hypothyroidism have a 
second endocrine disease, the most common being the T2DM (6) but others included 
hyperparathyroidism (2), T1DM (1), hypoparathyroidism (1) and panhypopituitarism 
(1). 
 
SLE&Hyperthyroidism 
We identified 10 patients with clinical hyperthyroidism (1.41 % of the total of the UCLH 
SLE cohort). Among these patients, we found, eight (80% of the total), had positive 
anti-thyroid antibodies one had no anti-thyroid antibodies and in one patient we could 
not find a record of the antibody results. 
Analysing the temporal relationship between SLE and endocrine disease, the endocrine 
disorder appeared later than SLE in six patients [ range: 2-17 years; mean: 8.6 years; 
median: 7 years]. In four cases, it appeared before [ range: 2-26 years; mean: 17.25 
years; median: 20.5 years]. One patient with hyperthyroidism had another endocrine 
disease (secondary hyperparathyroidism). 
 
SLE&Type 1 DiabetesMellitus  
We found three patients with T1DM1 (0.42 % of the total of our SLE cohort). 
Each developed their endocrine disease before the SLE [ range: 11-29 years, mean: 20 
years; median: 20 years]. One of them had a second endocrine disease 
(hypothyroidism). 
 
SLE&Type 2 DiabetesMellitus  
We identified 10 patients with T2DM (1.41 % of the total of our SLE cohort) with a 
range between 32 and 64 years old.  
In nine of these patients, the endocrine disease developed after SLE was diagnosed       
[range: 3 months-24 years; mean: 12.9 years; median: 8.5 years]. In one patient, the 
DM developed subsequently. In five patients, the T2DM was steroid-induced, four had 
a spontaneous T2DM and in one patient, there were insufficient data to be certain. 
50% of these patients had a second endocrine disease (each with hypothyroidism). 
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SLE&Hyperparathyroidism 
We found five patients who also had hyperparathyroidism which is the 0.70 % of our 
SLE cohort. 
The hyperparathyroidism appeared later than the SLE in all patients [range: 11-34 
years; mean: 23 years; median: 29 years]. One patient (0.14%) had a primary 
hyperparathyroidism due to parathyroid adenoma and the other four patients (0.56%) 
had secondary hyperparathyroidism due to a chronic renal failure as a result of lupus 
nephritis. Two of the SLE patients who had hyperparathyroidism also had 
hypothyroidism. One of them had hyperthyroidism as a second endocrine disease. 
 
SLE&OtherEndocrineDiseases 
None of our SLE patients was diagnosed with Addison’s disease.  
In contrast, other endocrine diseases were found in two patients; one with a 
panhypopituitarism, the other with hypoparathyroidism associated with 
hypothyroidism (both of these diseases developed later than the SLE). 
 
Prognosis in terms of deaths comparing SLE patients with and without endocrine 
disease. 
108 of the patients in our 708 SLE cohort (15.25%) have died during the follow-up of 
almost 40 years (see table 3).  Among those with concomitant endocrine disease 16.36 
% (9/55) have died, whereas in SLE patients without endocrine disease the figure was 
15.16 % (99/653). That result is not statistically significant by Chi-square. 
The most common cause of death in the group with endocrine disease was sepsis (3). 
Other causes were: cerebral haemorrhage (1), large granular lymphocyte leukemia (1), 
pulmonary hypertension (1), cancer (1), heart failure (1) and unknown (1). 88.8% were 
Caucasian and only one patient was Asian. Seven patients were on high doses of 
corticosteroids (> 20 mg of prednisolone) plus immunosuppressive treatment; one 
patient only was on medium doses of corticosteroids (from 10 to 20 mg of 
prednisolone) and the other  was on low doses of corticosteroids (< 10 mg of 
prednisolone). 
Among the SLE patients without endocrine disease, the most common causes of death 
were infection (28%) and cancer (26%). Other causes were: heart failure, pulmonary 
embolism, haemolytic anaemia, myocardial infarction, suicide and liver failure. In this 
group, 63.6% were Caucasian (63/99); 24.2% were Afro-Caribbean (24/99), 11.1% were 
Asian (11/99) and only one was South-Asian. 
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DISCUSSION: 
Our study focused on a careful review of the 708 SLE patients cohort at UCLH followed 
for almost 40 years to determine how often endocrinopathies occurred. We found that 
the most frequent diseases were hypothyroidism (37/708, 5.22%), hyperthyroidism 
(10/708; 1.41%) and T2DM (10/708; 1.41 %). Other endocrine disorders observed were 
primary hyperparathyroidism (1/708, 0.14 %), secondary hyperparathyroidism (4/708; 
0.56%) and T1DM (3/708, 0.42 %). Isolated cases of hypoparathyroidism and 
panhypopituitarism were identified.  
A close relationship between the immune and endocrine system is well established. [20-
23] Although concomitant endocrine diseases are not the most common or feared 
complications for SLE patients, they are important to diagnose and treat. The 
symptoms caused by endocrinopathies may closely mimic the clinical problems due to 
SLE, but the treatment is often very different. Thus, thyroxine may well resolve a lupus 
patient’s fatigue if it is caused by hypothyroidism rather than lupus activity. 
The prevalence of hypothyroidism in Great Britain is around 1-2% which is 10 times 
more common in women than in men (There are some studies in Northern Europe, 
Japan and USA which have found the prevalence range between 0.6 and 12 per 1000 
women and between 1.3 and 4.0 in men investigated)25 Our cohort had a percentage 
of clinical hypothyroidism of 5.22%. While the literature confirmed an increased rate of 
hypothyroidism in SLE patients, the prevalence rates in different studies differ 
substantially. Ong et al,2 Antonelli et al,6 and an earlier study from our UCLH cohort4 
showed similar results to this report (3.7%, 5.9% and 5.7% respectively), whereas other 
studies such as Molina et al,11 and Domingues et al,13 reported a higher prevalence       
( 19% and 21.5% respectively). This difference is probably explained by the inclusion in 
these latter studies of both the clinical and subclinical hypothyroidism. 
The prevalence of hyperthyroidism in Great Britain is around 0.2-2% in women and 10 
times less prevalent in men in iodine-replete communities.25 1.41% of patients in our 
cohort (10/708) had this endocrine disease, a figure within the range of the general 
population. The literature shows slightly higher results in terms of the frequency with 
which hyperthyroidism complicates SLE. Thus, Watad et al,1 and Ong et al,2 reported 
2.59% and 2.6%, respectively. Chan et al,14 reported a prevalence of 5.8% of 
hyperthyroidism in a study of 69 SLE patients. However, only 2.9% had a clinical 
hyperthyroidism, a figure thus closely resembling our results. 
It is possible we have under-estimated the prevalence of autoimmune thyroid disease. 
In a previous study we reported the prevalence of anti-thyroglobuline and anti-
microsomals thyroid antibodies is 13.5% and 12.5% respectively in the first 500 
patients in the cohort 32. However, we have had a low threshold to repeat the thyroid 
function test throughout the follow-up on our patients so we believe that the number 
of patients with clinically overt hypo (or hyperthyroidism) thyroid disease is likely to be 
accurate. 
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The prevalence of diabetes mellitus in the general population in Great Britain is about 
9% (according to Diabetes UK) and 10.4%,27 in Spain (both studies reported around 
10% of T1DM and 90% of T2DM). Only 1.83% of patients in our lupus cohort had this 
concomitant disease. Similar results to ours (1.85%) in a previous study of our UCLH 
cohort,7 and a slightly higher prevalence were reported by Gallego et al,10 (3.3%) in a 
cohort of 304 SLE patients reviewed in Spain. Thus, the prevalence of diabetes mellitus 
seems to be much lower in the different SLE cohorts compared to the general 
population. The reason could be that lupus patients are mostly diagnosed at an early 
age (between 15-45 years old) while, it is well established, that T2DM is more likely to 
develop over the age of 45 years and this increase becomes exponential from 60 
years.[24,28] 
Reviewing the literature, we did not find any report linking SLE and 
hyperparathyroidism. In our cohort, 0.70% of patients reviewed (5/708) had both. In 
four patients, it was probably a secondary hyperparathyroidism due to lupus kidney 
disease. One SLE patient had primary hyperparathyroidism as a result of a parathyroid 
adenoma. Thus, the presence of hyperparathyroidism in patients with lupus is most 
likely to be linked to renal disease as a result of lupus. 
None of our SLE patients have developed Addison’s disease. 
In our series (in general), the endocrine disease tended to develop after the SLE 
diagnosis. Thus, we observed this sequence in patients with T2DM (9/10, 90%) or 
hyperparathyroidism (5/5; 100%). Around 60% of patients with hypothyroidism 
(17/28) and hyperthyroidism (6/10), developed their endocrine disease following the 
Lupus diagnosis. However, T1DM was an exception. Each of the three T1DM patients 
developed the problem before the lupus diagnosis. 
A greater risk of having a second endocrine disease was identified in those patients 
with SLE associated with an endocrine disorder. In those with hypothyroidism, we 
observed that 32.43% (12/37) had more than one endocrine disease, the most 
common being T2DM. Among those SLE patients with hyperthyroidism, 10% 
developed a second endocrine disease. The occurrence of second endocrinopathy in 
the other endocrine diseases varied; T1DM and T2DM (46.15%) and 
hyperparathyroidism (60%). Hypothyroidism was the most common second endocrine 
disease in these different patients. 
 All the patients with diabetes mellitus (type I and II) who had developed a second 
endocrine disease (6) had hypothyroidism. 50% (6/12) SLE patients with 
hypothyroidism who had a second endocrine disease developed T2DM. Subekti et al,26 
observed a higher occurrence of hypothyroidism in patients with T2DM. 
 We analysed our cohort to determine whether those SLE patients who developed 
endocrine disease concomitantly had a poorer prognosis. The occurrence of death in 
SLE patients was similar in both groups (16.36% with endocrinopathy versus 15.16% 
without endocrine disease).  
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CONCLUSION: 
In our cohort of 708 SLE patients followed for almost 40 years, we report a 
concomitant endocrinopathy in 7.76%, the most common being hypothyroidism 
(5.22%). Interestingly, 21.8 % of our SLE plus endocrinopathy patients also have an 
increased risk of developing a second endocrine disease. However, our SLE patients 
with a concomitant endocrine disease had similar outcomes (in term of death) 
compared to those without an associated endocrine disease. 
Our data are broadly in line with results from other studies, but the number of patients 
we have studied, was generally bigger and our follow-up was much longer. It is 
important to capture endocrine diseases in SLE as the symptoms they cause may 
mimic SLE features but require quite distinct treatment. 
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